Author of the publication

N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma

, , , , , , , , , , , , , , , , , , and . Neuro Oncol, 21 (1): 95-105 (January 2019)
DOI: 10.1093/neuonc/noy161